ArticleJournal of nanobiotechnology2026
The stimuli-responsive CRISPR-Cas12a system for modulating the selective aggregation of cell membrane receptors.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
While CRISPR systems exhibit remarkable programmability in the field of nucleic acid editing, their extension to protein engineering faces a fundamental challenge, namely the traditional CRISPR tools lack the design to efficiently convert stimulus signals into the selective clustering of membrane receptors. This study develops a stimulus-responsive membrane-confined CRISPR-Cas12a platform that enhances selective clustering of membrane receptors for functional regulation. Specifically, a membrane-anchored DNA tetrahedral framework (TD-apt) was designed, which leverages vascular endothelial growth factor (VEGF) to activate Cas12a. Compared with unconfined CRISPR-Cas12a, membrane-confined CRISPR-Cas12a exhibits stronger cleavage activity, the interaction between the cellular-mesenchymal epithelial transition factor (c-Met) receptor and transferrin receptor (TfR) on A549 cells was efficiently modulated by nucleic acid assembly. This manipulation selectively inhibited c-Met function through spatial steric hindrance of TfR, modulating cellular behavior. Notably, the system's generality was validated by engineering of c-Met homodimerization for activation. This cascading regulatory paradigm of environmental sensing (VEGF response)-nucleic acid computation (CRISPR-based nucleic acid molecular computation)-protein assembly (receptor topological remodeling) effectively extends CRISPR's application boundaries to the field of non-genetic regulation protein-protein interaction (PPI) and establishes a versatile toolkit for dynamic and precise functional regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.